Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)
Cladribine Tablets in Highly-active Relapsing Multiple Sclerosis - Real-World Effectiveness in UK Clinical Practice (CAMELOT-MS)
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
This observational or N/A phase trial investigates Relapsing-Remitting Multiple Sclerosis and is currently completed. Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany leads this study, which shows 12 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Mar 2025 — Present [monthly]
Completed
-
Jan 2025 — Mar 2025 [monthly]
Completed
-
Sep 2024 — Jan 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2024 — Jul 2024 [monthly]
Completed
Status: Active Not Recruiting → Completed
▶ Show 7 earlier versions
-
Oct 2023 — Jan 2024 [monthly]
Active Not Recruiting
-
Jul 2023 — Oct 2023 [monthly]
Active Not Recruiting
-
Dec 2022 — Jul 2023 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Jun 2022 — Dec 2022 [monthly]
Recruiting
-
Dec 2021 — Jun 2022 [monthly]
Recruiting
-
Nov 2021 — Dec 2021 [monthly]
Recruiting
-
Sep 2021 — Nov 2021 [monthly]
Recruiting
First recorded
Aug 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Merck Serono Limited, UK
For direct contact, visit the study record on ClinicalTrials.gov .